Adoptive immunotherapy for cancer: building on success

By L. Gattinoni, D. Powell, S. Rosenberg, N. Restifo. Nature reviews. Immunology, 2006

904 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/b5ecb9f169de2ce29c4a5ba0d25817a5dcfeeea1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. N. Restifo
2. S. Rosenberg
3. Lieping Chen
4. M. Dudley
5. D. Pardoll
6. L. Gattinoni
7. C. June
8. V. Bronte

In Oncology

1. S. Rosenberg
2. N. Restifo
3. Lieping Chen
4. C. June
5. D. Pardoll
6. M. Dudley
7. L. Gattinoni
8. I. Melero

Citations in the corpus

• Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells (2009, background): “T cell proliferative and survival capacities have been correlated with tumor responses in mice and humans receiving adoptive T cell–based therapie”
• Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. (2010, result): “Adoptive transfer into wild-type mice bearing a subcutaneous MCA203 fibrosarcoma was without effect on tumor growth, unless preceded by myeloid and lymphoid ablation (Figure 4B), as reported for other adoptive cell therapy protocols (Gattinoni et al., 2006; Ugel et al., 2010).”
• Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells (2011, background): “…protocols typically consist of isolating tumor-infiltrating lymphocytes (TILs) or peripheral CD8+ T cells from the patient before expanding the cells ex vivo, by either anti-CD3 mAb or peptide stimulation in the presence of IL-2, and then reinjecting them into the patient (Gattinoni et al., 2006).”
• Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. (2008, background): “Discussion The inability of adoptively transferred T cells to persist in vivo has correlated with a lack of efficacy in clinical trials of adoptive immunotherapy for infections and cancer and has been suggested to result from differentiation during in vitro culture (9, 16, 17).”
• Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “, immunostimulants to increase the immunogenicity of tumour cells and adoptive transfer of cultured activated T lymphocytes (adoptive T-cell therapy”
• Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma (2008, background): “The chimeric antigen receptor we describe was derived from a combination of an antibody and a T cell receptor, but retargeting may also be achieved by cloning the MHC-peptide–binding α and β chains of the native T cell receptor (TCR-αβ) itself and transferring them to polyclonal T cell”
• A human memory T-cell subset with stem cell-like properties (2011, methodology): “Notably, T EM cells, which resemble cell populations used in current clinical trials for adoptive immunotherap”
• B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019, background): “Successful adoptive transfer of tumor-specific T cells, including CAR T cells, in humans has most commonly followed some form of lymphodepleting conditioning (13, 14, 24–26), which has been demonstrated to enhance T cell–mediated antitumor immunity via multiple potential mechanisms, including reduct”